SCHEMBL1401588

SCHEMBL1401588

CCOc1cc(C)c(N)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
TP53 P04637 3/20 0.47
CYP3A4 P08684 3/20 0.47
ALDH1A1 P00352 5/20 0.46
NQO1 P15559 1/20 0.46
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
NPC1 O15118 2/20 0.42
APOBEC3G Q9HC16 1/20 0.42
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10974871 0.87 TSHR (0.42) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL18644563 0.86 LTA4H (0.41) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL5028320 0.82 ALDH1A1 (0.42) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL7225914 0.80 TSHR (0.44) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL4570827 0.80 NQO1 (0.50) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL6460166 0.79 TSHR (0.51) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL19885259 0.78 NQO1 (0.48) TSHRTDP1TP53CYP3A4ALDH1A1
SCHEMBL7220329 0.77 TSHR (0.54) TSHRTP53NPC1RAB9AMAPT
SCHEMBL19480454 0.77 TSHR (0.54) TSHRTP53NPC1RAB9AMAPT
SCHEMBL25235299 0.77 GAA (0.51) TDP1ALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207983-B Use of a lubricating composition 国际壳牌研究有限公司 2022-11-18 CN disclosed
CN-106928126-B Amide derivative, preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2019-12-20 CN disclosed
CN-106928126-A A kind of amide derivatives and preparation method thereof and application pharmaceutically 四川海思科制药有限公司 2017-07-07 CN disclosed
US-8026245-B2 HIV replication inhibiting purine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-09-27 US disclosed
EP-1668011-B1 HIV REPLICATION INHIBITING PURINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2011-03-02 EP disclosed
EP-1668011-B1 HIV REPLICATION INHIBITING PURINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2011-03-02 EP disclosed
US-7465730-B2 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds MERCK & CO. INC. (US) 2008-12-16 US disclosed
US-20060293330-A1 Hiv replication inhibiting purine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 US disclosed
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds MERCK SHARP & DOHME CORP. 2006-07-13 US disclosed
EP-1668011-A2 HIV REPLICATION INHIBITING PURINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-14 EP disclosed
EP-1539168-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2005028479-A2 HIV REPLICATION INHIBITING PURINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-31 WO disclosed
WO-2004006836-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS MERCK & CO., INC. (US) 2004-01-22 WO disclosed
CN-1061962-A INDENOINDOLE COMPOUNDS UNIV BATH (GB) 1992-06-17 CN disclosed
EP-0043716-B1 PHOTOSENSITIVE COMPOSITION AND PATTERN FORMING PROCESS USING SAME Hitachi, Ltd. (JP) 1985-04-10 EP disclosed
US-4409313-A Powder deposition to form pattern on light imaged photosensitive diazonium salt coating having salt of aromatic amine HITACHI, LTD. (JP) 1983-10-11 US disclosed
US-4377630-A COMPRISING AN AROMATIC DIAZONIUM SALT AND N,N-DIALKYL ANILINE SALT HITACHI, LTD. (JP) 1983-03-22 US disclosed
EP-0043716-A2 Photosensitive composition and pattern forming process using same Hitachi, Ltd. (JP) 1982-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds GRIN2C, CACNA1C, CACNG4 TSHR 2114/4885TDP1 2908/4885TP53 3787/4885
US-20060293330-A1 Hiv replication inhibiting purine derivatives NSUN2, PRMT7, NNMT TSHR 4203/4885TDP1 1989/4885TP53 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.